论文部分内容阅读
目的:探讨CD44V6与CK19在非小细胞肺癌(NSCLC)组织中的表达及其与临床病理特征的关系。方法:采用免疫组织化学技术检测60例肺癌及20例正常良性病变肺组织标本中CD44V6与CK19的表达状况。结果:CD44V6在NSCLC组织中的表达显著高于正常肺组织(P<0.05),且与临床分期、淋巴结转移成正相关,P<0.05。CK19在NSCLC组织(85.0%)和正常肺组织(90.0%)中均为高表达,与病理类型、组织分化和淋巴结转移等无关。结论:CD44V6高表达与NSCLC侵袭转移密切相关,可作为判断肿瘤转移及预后的重要生物学指标。CK19高表达与临床病理特征无关。
Objective: To investigate the expression of CD44V6 and CK19 in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features. Methods: Immunohistochemistry was used to detect the expression of CD44V6 and CK19 in 60 lung cancer specimens and 20 normal benign lesions. Results: The expression of CD44V6 in NSCLC tissues was significantly higher than that in normal lung tissues (P <0.05), and positively correlated with clinical stage and lymph node metastasis (P <0.05). CK19 was highly expressed in both NSCLC tissues (85.0%) and normal lung tissues (90.0%), which was not associated with pathological types, tissue differentiation and lymph node metastasis. Conclusion: The high expression of CD44V6 is closely related to the invasion and metastasis of NSCLC, which may be used as an important biological indicator to judge the metastasis and prognosis of tumor. CK19 high expression has nothing to do with clinicopathological features.